Search
Ibrutinib
go.drugbank.com/drugs/DB09053ApprovedInvestigationalIt is designated as a targeted covalent drug and presented as a promising activity in B-cell malignancies in clinical trials. … Ibrutinib is a small molecule that acts as an irreversible potent inhibitor of Burton's tyrosine kinase.
Categories: Heterocyclic Compounds, 2-Ring, Cytochrome P-450 SubstratesSynonyms: 1-[(3R)-3-[4-Amino-3-(4-phenoxyphenyl)-1H-pyrazolo[3,4-d]pyrimidin-1-yl]piperidin-1-yl]prop-2-en-1-oneDoxazosin
go.drugbank.com/drugs/DB00590ApprovedInvestigationalDoxazosin is an alpha-1 antagonist used for the treatment of benign prostatic hypertrophy (BPH) symptoms and hypertension. … [A180661] Because of its long-lasting effects, doxazosin can be administered once a day.[A180649] It is marketed by Pfizer and was initially approved by the FDA in 1990.[L7285]
Synonyms: 1-(4-Amino-6,7-Dimethoxy-2-quinazolinyl)-4-(1,4-benzodioxan-2-ylcarbonyl)piperazin, 1-(4-Amino-6,7-dimethoxy-2-chinazolinyl)-4-(2,3-dihydro-1,4-benzodioxixin-2-ylcarbonyl)piperazinInternational brands: Cardura-2, Cardura-4Nimodipine
go.drugbank.com/drugs/DB00393ApprovedInvestigationalNimodipine is a 1,4-dihydropyridine calcium channel blocker. It acts primarily on vascular smooth muscle cells by stabilizing voltage-gated L-type calcium channels in their inactive conformation.
Categories: P-glycoprotein inhibitors, Cytochrome P-450 SubstratesSynonyms: isopropyl 2-methoxyethyl 1,4-dihydro-2,6-dimethyl-4-(m-nitrophenyl)-3,5-pyridinedicarboxylate, isopropyl 2-methoxyethyl 1,4-dihydro-2,6-dimethyl-4-(3-nitrophenyl)-3,5-pyridinedicarboxylatePrazosin
go.drugbank.com/drugs/DB00457ApprovedInvestigational[L5828] It belongs to the class of drugs known as alpha-1 antagonists. … Prazosin is a drug used to treat hypertension. Prazosin is marketed by _Pfizer_ and was initially approved by the FDA in 1988.
Synonyms: 2-(4-(2-Furoyl)piperazin-1-yl)-4-amino-6,7-dimethoxyquinazoline, 1-(4-Amino-6,7-dimethoxy-2-quinazolinyl)-4-(2-furanylcarbonyl)piperazineCategories: Heterocyclic Compounds, 2-Ring, P-glycoprotein inhibitorsLinagliptin
go.drugbank.com/drugs/DB08882ApprovedInvestigationalLinagliptin was approved by the FDA on May 2, 2011[L9557]. … Linagliptin is a DPP-4 inhibitor developed by Boehringer Ingelheim for the treatment of type II diabetes [L9557].
Mixtures: GLYXAMBI® 25 MG/ 5 MG, GLYXAMBI® 25 MG/ 5 MGCategories: Heterocyclic Compounds, 2-Ring, P-glycoprotein inhibitorsDarunavir
go.drugbank.com/drugs/DB01264ApprovedInvestigational[L9227] Darunavir is being studied as a possible treatment for SARS-CoV-2, the coronavirus responsible for COVID-19, due to in vitro evidence supporting its ability to combat this infection. … Darunavir is a protease inhibitor used with other HIV protease inhibitor drugs as well as [ritonavir] for the effective management of HIV-1 infection.
Mixtures: REZOLSTA 800 MG/150 MG FİLM KAPLI TABLET, 30 ADET, FURTHAS®R TABLETAS RECUBIERTASCategories: P-glycoprotein inducers, P-glycoprotein inhibitorsCefotaxime
go.drugbank.com/drugs/DB00493ApprovedInvestigationalCefotaxime is a third-generation cephalosporin antibiotic. Like other third-generation cephalosporins, it has broad spectrum activity against Gram positive and Gram negative bacteria.
Mixtures: SEFOTAK 1 G IM ENJEKSİYONLUK TOZ İÇEREN FLAKON, 1 ADETCategories: Heterocyclic Compounds, 2-RingCefdinir
go.drugbank.com/drugs/DB00535ApprovedInvestigationalCefdinir was approved by the FDA in 1997 to treat a variety of mild to moderate infections and was initially marketed by Abbvie. … Cefdinir, also known as Omnicef, is a semi-synthetic, broad-spectrum antibiotic belonging to the third generation of the cephalosporin class.
Synonyms: (6R,7R,Z)-7-(2-(2-aminothiazol-4-yl)-2-(hydroxyimino)acetamido)-8-oxo-3-vinyl-5-thia-1-aza-bicyclo[4.2.0]oct-2-ene-2-carboxylic acid, (6R,7R)-7-{2-(2-Amino-thiazol-4-yl)-2-[(Z)-hydroxyimino]-acetylamino}-8-oxo-3-vinyl-5-thia-1-aza-bicyclo[4.2.0]oct-2-ene-2-carboxylic acidInternational brands: Omnicef RSotorasib
go.drugbank.com/drugs/DB15569ApprovedInvestigational[A187547] Sotorasib was granted FDA approval on May 28, 2021,[L34288] followed by the European Commission's approval on January 6, 2022.[L56070] … [A187550] Mutant KRAS discovered in 1982 but was not considered a druggable target until the mid-2010s.[A235168] It is the first experimental KRAS inhibitor.
Categories: P-glycoprotein inhibitors, Cytochrome P-450 SubstratesSynonyms: 6-fluoro-7-(2-fluoro-6-hydroxyphenyl)-(1M)-1-[4-methyl-2-(propan-2-yl)pyridin-3-yl]-4-[(2S)-2- methyl-4-(prop-2-enoyl)piperazin-1-yl]pyrido[2,3-d]pyrimidin-2(1H)-one, Kras G12C inhibitor 9Nefazodone
go.drugbank.com/drugs/DB01149ApprovedWithdrawnDrug-induced hepatic injuries were associated with an risk of elevated need for a liver transplant, or even death, with the incidence of severe liver damage was shown to be approximately 1 in 250,000 to … On May 20, 2004, Bristol-Myers Squibb discontinued the sale of Serzone in the United States.
Categories: Serotonin antagonist and reuptake inhibitors (SARIs), P-glycoprotein inducersSynonyms: 1-(3-(4-(m-Chlorophenyl)-1-piperazinyl)propyl)-3-ethyl-4-(2-phenoxyethyl)-delta2-1,2,4-triazolin-5-one